J&J lowers 2022 income and earnings expectations, stops giving Covid vaccine gross sales steering

Johnson & Johnson on Tuesday lowered its full-year gross sales and earnings outlook, and stopped offering Covid-19 vaccine income steering as a result of a worldwide provide surplus and demand uncertainty.

J&J is now forecasting 2022 gross sales of $94.8 billion to $95.8 billion, about $1 billion decrease than the steering offered in January. The corporate lowered its full-year adjusted earnings per share by 25 cents to between $10.15 and $10.35, from a earlier forecast of $10.40 to $10.60.

CFO Joe Wolk, throughout J&J’s earnings name later Tuesday morning, mentioned the corporate faces financial headwinds from larger enter prices in addition to rising labor, vitality and transportation costs. J&J additionally confronted provide constrains on some commodities, Wolk mentioned mentioned.

J&J reported first-quarter gross sales of $23.4 billion, barely lacking Wall Road expectations however rising 5% over the identical quarter final 12 months. The corporate posted earnings of $2.67 cents per share, beating expectations and rising 3.1% over the identical interval of 2021. J&J reported web earnings of $5.15 billion, an almost 17% lower over the primary quarter of 2021.

Here is how J&J carried out in contrast with what Wall Road anticipated, primarily based on analysts’ common estimates compiled by Refinitiv:

  • Adjusted EPS: $2.67 per share, vs. $2.58 anticipated
  • Income: $23.4 billion, vs. $23.6 billion anticipated

The corporate offered $457 million of its Covid vaccine globally. Wolk mentioned Tuesday that growing nations have restricted capability by way of refrigeration and getting pictures in arms, which has created a backlog of the vaccines. When requested about now not offering a gross sales outlook for the pictures, Wolk mentioned it was uncommon to supply steering for a selected product to start with.

“We did it final 12 months as a result of we understood the Road had an expectation or no less than an pleasure round understanding how vaccine gross sales would possibly play out nevertheless it was by no means materials,” Wolk advised CNBC’s Meg Tirrell on “Squawk Box,” noting the vaccine will not be for revenue and would not influence the corporate’s backside line. He mentioned Covid vaccine gross sales met J&J’s inner expectations.

The corporate’s shares had been up greater than 3% in afternoon buying and selling Tuesday, after earlier hitting a 52-week excessive.

J&J reported $12.87 billion in pharmaceutical gross sales, a rise of 6.3% over the identical quarter final 12 months. The corporate’s medical units enterprise grew by 5.9% to $6.97 billion in gross sales in contrast with the primary quarter of 2021. Gross sales at J&J’s shopper well being enterprise, which it’s spinning off right into a separate publicly traded firm, declined 1.5% to $3.59 billion.

In prescription drugs, Wolk mentioned new prescriptions slowed in early January when the Covid omicron variant was sweeping the U.S., however picked up in February and March. He mentioned J&J’s medical units enterprise led the corporate’s development with an uptick on the whole and superior surgical procedure in addition to orthopedics.

Ashley McEvoy, who heads the medical units enterprise, mentioned on the corporate’s earnings name that diagnostic procedures had been flat within the U.S. when omicron infections surged in January, and surgical procedures declined by about 10%. Nonetheless, McEvoy mentioned she expects surgical procedures to rise above 2019 ranges in April as Covid infections have declined, easing the pressure on hospitals.

Wolk mentioned shopper well being was hit by provide constraints for some product elements and packaging supplies, notably in pores and skin well being and wonder. Nonetheless, he mentioned demand is robust for shopper well being merchandise, notably over-the-counter medicines reminiscent of Tylenol and Motrin, and J&J expects pores and skin well being and wonder to rebound later within the 12 months.

J&J’s board has accredited a 6.6% quarterly dividend enhance to $1.13 per share as a result of firm’s robust 2021 efficiency, the corporate introduced.


Leave a Reply

Your email address will not be published.